Table 2.
Statistical analysis to determine the significant way of pharmacotherapy for ADHD
| Variable | Survival duration (yr) | Simple cox regression (ref. maintenance) | Multiple cox regression (ref. maintenance) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||||||
| Median | CI | Mean | SE | HR | CI | p value | HR | CI | p value | |||
| Group | ||||||||||||
| ATX and MPH | 1.44 | 1.24−1.68 | 2.86 | 0.13 | 1.00 | - | - | 1.00 | - | - | ||
| COM | 5.84 | 2.65−10.41 | 6.00 | 0.65 | 0.39 | 0.27−0.57 | < 0.0001 | 0.40 | 0.27−0.58 | < 0.0001 | ||
| SEP | 3.78 | 2.76−4.95 | 4.72 | 0.37 | 0.57 | 0.45−0.73 | < 0.0001 | 0.57 | 0.45−0.73 | < 0.0001 | ||
| Sex | ||||||||||||
| Male | 1.76 | 1.53−2.16 | 3.37 | 0.14 | 1.00 | - | - | 1.00 | - | - | ||
| Female | 1.61 | 1.24−2.15 | 2.88 | 0.23 | 1.15 | 0.97−1.37 | 0.0986 | 1.16 | 0.98−1.37 | 0.0930 | ||
| Age | ||||||||||||
| < 18 | 1.90 | 1.64−2.28 | 3.40 | 0.14 | 1.00 | - | - | 1.00 | - | - | ||
| ≥ 18 | 1.25 | 0.91−1.53 | 2.84 | 0.25 | 1.24 | 1.05−1.47 | 0.0137 | 1.21 | 1.02−1.44 | 0.0270 | ||
ADHD, attention-deficiency/hyperactivity disorder; ATX, group treated with atomoxetine only; MPH, group treated with methylphenidate only; SEP, group exposed to ATX and MPH but separately used; COM, group exposed to ATX and MPH with combined use; CI, confidence interval; HR, hazard ratio; SE, standard error.